The Alliance for Benzodiazepine Best Practices

The Alliance for Benzodiazepine Best Practices is fighting a health crisis. Like the opioids, the prescription rate of benzodiazepines (such as Xanax, Valium, Klonopin and Ativan) is extremely excessive, with devastating results similar to those experienced by so many opioid users. For many users, this includes losses ranging from partial incapacity to complete dependence, with a withdrawal that is far more difficult than that experienced by opioid users. For a surprising number, it results in death.

Our mission is to make evidence-based improvements to the prescribing of benzodiazepines and Z-drugs (a related drug class, containing Lunesta, Ambien and others). Our primary objective is to significantly reduce the number of benzodiazepine withdrawal sufferers by reducing the number of improper new prescriptions for benzodiazepines and Z-drugs. Our focus is to illustrate the problems associated with benzodiazepines, illuminate alternatives to their use, and provide tools for clinicians to assist benzodiazepine withdrawal syndrome sufferers, and provide tools for patients to assist them in their withdrawal and recovery process.